Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDChronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, allergic disease, chronic obstructive pulmonary disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 22026-09-04NCT07059091

5 results · Page 1 of 1

23 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Baylor College of MedicineHoustonUnited States306
Columbia UniversityNew YorkUnited States154
Cornell UniversityNew YorkUnited States2
Duke University Medical CenterDurhamUnited States52
Henry Ford HealthDetroitUnited States75
Johns Hopkins UniversityBaltimoreUnited States13
Mount Sinai, Icahn School of MedicineNew YorkUnited States3
National Jewish HealthDenverUnited States72
Northwestern UniversityChicagoUnited States727
Pacific Northwest Airways - VA Puget Sound Healthcare System, SeattleSeattleUnited States1
Rush University Medical CenterChicagoUnited States283
Temple UniversityPhiladelphiaUnited States50
University of AlabamaBirminghamUnited States29
University of Arizona- TusconTucsonUnited States1
University of FloridaJacksonvilleUnited States15
University of Illinois at ChicagoChicagoUnited States8
University of IowaIowa CityUnited States284
University of Kansas Medical CenterKansas CityUnited States240
University of MichiganAnn ArborUnited States538
University of PittsburghPittsburghUnited States137
University of San FranciscoSan FranciscoUnited States2
University of VermontColchesterUnited States4
Vanderbilt University Medical CenterNashvilleUnited States40